THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 21 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $2,478,000 | -51.0% | 2,500,000 | -50.0% | 0.00% | -50.0% |
Q1 2018 | $5,059,000 | +32.4% | 5,000,000 | +42.9% | 0.00% | +100.0% |
Q4 2017 | $3,821,000 | -10.8% | 3,500,000 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $4,285,000 | -36.5% | 3,500,000 | -30.0% | 0.00% | -33.3% |
Q2 2017 | $6,746,000 | – | 5,000,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Context Capital Management, LLC | 13,473,000 | $12,756,000 | 1.74% |
Shaolin Capital Management LLC | 14,065,000 | $13,281,000 | 0.93% |
ZAZOVE ASSOCIATES LLC | 3,773,000 | $3,584,000 | 0.44% |
FARALLON CAPITAL MANAGEMENT LLC | 56,695,000 | $53,806,000 | 0.32% |
Baupost Group | 30,000,000 | $28,396,000 | 0.26% |
Aequim Alternative Investments LP | 3,000,000 | $2,840,000 | 0.21% |
WOLVERINE ASSET MANAGEMENT LLC | 24,100,000 | $22,817,000 | 0.17% |
TENOR CAPITAL MANAGEMENT Co., L.P. | 5,500,000 | $5,257,000 | 0.15% |
SSI INVESTMENT MANAGEMENT LLC | 1,750,000 | $1,648,000 | 0.12% |
GABELLI & Co INVESTMENT ADVISERS, INC. | 430,000 | $406,000 | 0.06% |